ImmunityBio (IBRX) Cash & Equivalents (2013 - 2026)

ImmunityBio (IBRX) has 14 years of Cash & Equivalents data on file, last reported at $205.2 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $205.2 million, up 238.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $205.2 million (up 238.27% YoY), and the FY2025 annual result was $88.3 million, down 38.41% from the prior year.
• Cash & Equivalents rose to $205.2 million in Q1 2026 per IBRX's latest filing, from $88.3 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $265.5 million in Q4 2023 and troughed at $36.4 million in Q1 2022.
• A 5-year average of $114.9 million and a median of $104.6 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2025 and 2026: Cash & Equivalents plunged 54.4% in 2025, then jumped 238.27% in 2026.
• A 5-year view of Cash & Equivalents shows it stood at $104.6 million in 2022, then soared by 153.68% to $265.5 million in 2023, then sank by 45.97% to $143.4 million in 2024, then tumbled by 38.41% to $88.3 million in 2025, then surged by 132.29% to $205.2 million in 2026.
• Business Quant data shows IBRX's Cash & Equivalents at $205.2 million in Q1 2026, $88.3 million in Q4 2025, and $60.2 million in Q3 2025.